Mechanisms for pituitary tumorigenesis: The plastic pituitary

Journal of Clinical Investigation

Volumn 112, Issue 11, 2003, Pages 1603-1618

  Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CORTICOTROPIN; DNA; ESTROGEN; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH FACTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HORMONE; LUTEINIZING HORMONE; MESSENGER RNA; NERVE GROWTH FACTOR; PROLACTIN; PROTEIN P16; PROTEIN P18; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; THYROTROPIN; TRANSFORMING GROWTH FACTOR;

ADENOHYPOPHYSIS; ALBRIGHT SYNDROME; CARCINOGENESIS; CARNEY COMPLEX; CELL DIFFERENTIATION; FAMILIAL CANCER; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MULTIPLE ENDOCRINE NEOPLASIA; PEDIGREE ANALYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0347951038     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20401     Document Type: Review

References (149)

1. Taniguchi, Y., Yasutaka, S., Kominami, R., and Shinohara, H. 2002. Proliferation and differentiation of rat anterior pituitary cells. Anat. Embryol. (Berl.). 206:1-11.
2. Levy, A., and Lightman, S. 2003. Molecular defects in the pathogenesis of pituitary tumours. Front. Neuroendocrinol. 24:94-127.
3. Asa, S.L., and Ezzat, S. 1998. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 19:798-827.
4. Faglia, G., and Spada, A. 2001. Genesis of pituitary adenomas: state of the art. J. Neurooncol. 54:95-110.
5. Prezant, T.R., and Melmed, S. 2002. Molecular pathogenesis of pituitary disorders. Current Opinion in Endocrinology & Diabetes. 9:61-78.
6. Jeffcoate, W.J., Pound, N., Sturrock, N.D., and Lambourne, J. 1996. Long-term follow-up of patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf). 45:299-303.
7. Olson, L.E., and Rosenfeld, M.G. 2002. Perspective: genetic and genomic approaches in elucidating mechanisms of pituitary development. Endocrinology. 143:2007-2011.
8. Semina, E.V., et al. 1996. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat. Genet. 14:392-399.
9. Netchine, I., et al. 2000. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat. Genet. 25:182-186.
10. Machinis, K., et al. 2001. Syndromic short stature in patients with a germline mutation in the lim homeobox lhx4. Am. J. Hum. Genet. 69:961-968.
11. Dattani, M.T., et al. 1998. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat. Genet. 19:125-133.
12. Liu, J., et al. 2001. Tbx19, a tissue-selective regulator of POMC gene expression. Proc. Natl. Acad. Sci. U. S. A. 98:8674-8679.
13. Lamolet, B., et al. 2001. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 104:849-859.
14. Pulichino, A.M., et al. 2003. Tpit determines alternate fates during pituitary cell differentiation. Genes Dev. 17:738-747.
15. Cohen, L.E., and Radovick, S. 2002. Molecular basis of combined pituitary hormone deficiencies. Endocr. Rev. 23:431-442.
16. Sornson, M.W., et al. 1996. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature. 384:327-333.
17. Li, S., et al. 1990 Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature. 347:528-S33.
18. Cushman, L.J., et al. 2001. Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary rumor susceptibility. Hum. Mol. Genet. 10:1141-1153.
19. Riepe, F.G., et al. 2001. Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J. Clin. Endocrinol. Metab. 86:4353-4357.
20. Osorio, M.G., et al. 2002. Pituitary magnetic resonance imaging and function in patients with growth hormone deficiency with and without mutations in GHRH-R, GH-1, or PROP-1 genes. J. Clin. Endocrinol. Metab. 87:5076-5084.
21. Teinturier, C., et al. 2002. Pseudotumor of the pituitary due to PROP-1 deletion. J. Pediatr. Endocrinol. Metab. 15:95-101.
22. Pellegrini, I., et al. 1994. Pit-1 gene expression in the human pituitary and pituitary adenomas. J. Clin. Endocrinol. Metab. 79:189-196.
23. Nakamura, S., et al. 1999. Prop-1 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 84:2581-2584.
24. Moons, D.S., et al. 2002. Pituitary hypoplasia and lactotroph dysfunction in mice deficient for cyclin-dependent kinase-4. Endocrinology. 143:3001-3008.
25. Horvath, E., Kovacs, K., and Scheithauer, B.W. 1999. Pituitary hyperplasia. Pituitary. 1:169-179.
26. Chanson, P., et al. 2001. Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study. J. Clin. Endocrinol. Metab. 86:3009-3015.
27. Scheithauer, B.W., et al. 1990. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc. 65:461-474.
28. Coogan, P.F., Baron, J.A., and Lambe, M. 1995. Parity and pituitary adenoma risk. J. Natl. Cancer Inst 87:1410-1411.
29. Severinghaus, A.E. 1937. Cellular changes in the anterior hypophysis with special references to its secretory activities. Physiol. Rev. 17:556-566.
30. Vidal, S., Horvath, E., Kovacs, K., Lloyd, R.V., and Smyth, H.S. 2001. Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia. Mod. Pathol. 14:20-28.
31. Childs, G.V. 2002. Development of gonadotropes may involve cyclic transdifferentiation of growth hormone cells. Arch. Physiol. Biochem. 110:42-49.
32. Ivarie, R., and Morris, J. 1983. Phenotypic switching in GH3 rat pituitary tumor cells: linked expression of growth hormone and another hormonally responsive protein. DNA. 2:113-120.
33. Vidal, S., et al. 2000. Transdifferentiation of somatotrophs to thytotrophs in the pituitary of patients with protracted primary hypothyroidism. Virchows Arch. 436:43-51.
34. Bevan, J.S., et al. 2002. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-1, and tumor size. J. Clin. Endocrinol. Metab. 87:4554-4563
35. Corsello, S.M., et al. 2003. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin. Endocrinol. (Oxf). 58:662-670.
36. Shupnik, M.A., et al. 1998. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. J. Clin. Endocrinol. Metab. 83:3965-3972.
37. Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R., and Melmed, S. 1999. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5:1317-1321.
38. Walker, B.E., and Kurth, L.A. 1993. Pituitary tumors in mice exposed prenatally to diethylstilbestrol. Cancer Res. 53:1546-1549.
39. Chaidarun, S.S., Swearingen, B., and Alexandet, J.M. 1998. Differential expression of estrogen receptor-β (ERβ) in human pituitary tumors: functional interactions with ERα and a tumor-specific splice variant. J. Clin. Endocrinol. Metab. 83:3308-3315.
40. Heaney, A.P., Fernando, M., and Melmed, S. 2002. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest. 109:277-283. doi:10.1172/JCI200214264.
41. Heaney, A.P., Fernando, M., Yong, W.H., and Melmed, S. 2002. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8:1281-1287.
42. Kovacs, K., Stefaneanu, L., Ezzat, S., and Smyth, H.S. 1994. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch. Pathol. Lab. Med. 118:562-565.
43. Vidal, S., et al. 2002. Prolactin-producing pituitary adenoma associated with prolactin cell hyperplasia. Endocr. Pathol. 13:157-165.
44. Muglia, L.J., Bethin, K.E., Jacobson, L., Vogt, S.K., and Majzoub, J.A. 2000. Pituitary-adrenal axis regulation in CRH-deficient mice. Endocr. Res. 26:1057-1066.
45. Mayo, K.E., et al. 1988. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol. Endocrinol. 2:606-612.
46. Asa, S.L., et al. 1992. Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology. 131:2083-2089.
47. Asa, S.L., Kelly, M.A., Grandy, D.K., and Low, M. J. 1999. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology. 140:5348-5355.
48. Carey, R.M., et al. 1984. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N. Engl. J. Med. 311:13-20.
49. Sano, T., Asa, S.L., and Kovacs, K. 1988. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr. Rev. 9:357-373.
50. Thorner, M.O., et al. 1982. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J. Clin. Invest. 70:965-977.
51. Schuff, K.G., et al. 2002. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J. Clin. Invest. 110:973-981. doi:10.1172/JCI200215912.
52. Friedman, E., et al. 1994. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J. Clin. Endocrinol. Metab. 78:568-574.
53. Petersenn, S., Heyens, M., Ludecke, D.K., Beil, F.U., and Schulte, H.M. 2000. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clin. Endocrinol. (Oxf). 52:35-42.
54. Ballare, E., et al. 2001. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86:3809-3814.
55. Ando, S., Sarlis, N.J., Oldfield, E.H., and Yen, P.M. 2001. Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J. Clin. Endocrinol. Metab. 86:5572-5576.
56. Chanson, P., et al. 1998. Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. Eur. J. Endocrinol. 139:157-160.
57. Faccenda, E., Melmed, S., Bevan, J.S., and Eidne, K.A. 1996. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas. Clin. Endocrinol. (Oxf). 44:341-347.
58. Lee, E.J., et al. 2001. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. J. Clin. Endocrinol. Metab. 86:3989-3995.
59. Barinaga, M., Bilezikjian, L.M., Vale, W.W., Rosenfeld, M.G., and Evans, K.M. 1985. Independent effects of growth hormone releasing factor on growth hormone release and gene transcription. Nature. 314:279-281.
60. Billestrup, N., Swanson, L.W., and Vale, W. 1986. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc. Natl. Acad. Sci. U. S. A. 83:6854-6857.
61. Lin, S.C., et al. 1993. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 364:208-213.
62. Salvatori, R., et al. 2001. Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clin. Endocrinol. (Oxf). 54:301-307.
63. Weinstein, L.S., et al. 1991. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 325:1688-1695.
64. Vallar, L., Spada, A., and Giannattasio, G. 1987. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 330:566-568.
65. Bertherat, J., Chanson, P., and Montminy, M. 1995. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol. Endocrinol. 9:777-783.
66. Struthers, R.S., Vale, W.W., Arias, C., Sawchenko, P.E., and Montminy, M.R. 1991. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature. 350:622-624.
67. Lania, A., et al. 1998. Constitutively active Gsα is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J. Clin. Endocrinol. Metab. 83:1624-1628.
68. Kirschner, L.S. et al. 2000. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet. 26:89-92.
69. Stratakis, C.A., et al. 1996. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). J. Clin. Endocrinol. Metab. 81:3607-3614.
70. Casey, M., et al. 2000. Mutations in the protein kinase A R1α regulatory subunit cause familial cardiac myxomas and Carney complex. J. Clin. Invest. 106:R31-38.
71. Gonsky, R., Herman, V., Melmed, S., and Fagin, J. 1991. Transforming DNA sequences present in human prolactin-secreting pituitary tumors. Mol. Endocrinol. 5:1687-1695.
72. Shimon, I., Huttner, A., Said, J., Spirina, O.M., and Melmed, S. 1996. Heparin-binding secretory transforming gene (hsr) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. J. Clin. Invest. 97:187-195.
73. Shimon, I., Hinton, D.R., Weiss, M.H., and Melmed, S. 1998. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. Clin. Endocrinol. (Oxf). 48:23-29.
74. Ezzat, S., Zheng, L., Zhu, X.-F., Wu, G.E., and Asa, S.L. 2002. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest. 109:69-78. doi:10.1172/JCI200214306.
75. McAndrew, J., Paterson, A.J., Asa, S.L., McCarthy, K.J., and Kudlow, J.E. 1995. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology. 136:4479-4488.
76. Paez-Pereda, M., et al. 2003. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc. Natl. Acad. Sci. U. S. A. 100:1034-1039.
77. Borrelli, E., Sawchenko, P.E., and Evans, R.M. 1992. Pituitary hyperplasia induced by ectopic expression of nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 89:2764-2768.
78. Woloschak, M., Roberts, J.L., and Post, K. 1994. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas. J. Clin. Endocrinol. Metab. 79:253-257.
79. Herman, V., Fagin, J., Gonsky, R., Kovacs, K., and Melmed, S. 1990. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71:1427-1433.
80. Alexander, J.M., et al. 1990. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86:336-340.
81. Berezin, M., and Karasik, A. 1995. Familial prolactinoma. Clin. Endocrinol. (Oxf). 42:483-486.
82. Tanaka, C., et al. 1998. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J. Clin. Endocrinol. Metab. 83:960-965.
83. Gadelha, M.R., et al. 2000. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J. Clin. Endocrinol. Metab. 85:707-714.
84. Simpson, D.J., et al. 2003. Genome-wide amplification and allelotyping of sporadic pituitary adenomas identify novel regions of genetic loss. Genes Chromosomes Cancer. 37:225-236.
85. Bates, A.S., et al. 1997. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J. Clin. Endocrinol. Metab. 82:818-824.
86. Crabtree, J.S., et al. 2001. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. U. S. A. 98:1118-1123.
87. Zhuang, Z., et al. 1997. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 57:5446-5451.
88. Chau, B.N., and Wang, J.Y. 2003. Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3:130-138.
89. Jacks, T., et al. 1992. Effects of an Rb mutation in the mouse. Nature. 359:295-300.
90. Zhu, J., et al. 1994. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J. Clin. Endocrinol. Metab. 78:922-927.
91. Woloschak, M., Roberts, J.L., and Post, K.D. 1994. Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors. Cancer. 74:693-696.
92. Woloschak, M., Yu, A., Xiao, J., and Post, K.D. 1996. Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int. J. Cancer. 67:16-19.
93. Kip1. Cell. 85:721-732.
94. Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J. Clin. Endocrinol. Metab. 84:3823-3830.
95. Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274:13886-13893.
96. -/- cells to signals that trigger apoptosis during pituitary tumor development. Oncogene. 22:361-369.
97. Riss, D., et al. 2003. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 63:2251-2255.
98. Kip1-deficient mice. Cell. 85:733-744.
99. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 12:2899-2911.
100. Frost, S.J., Simpson, D.J., Clayton, R.N., and Farrell, W.E. 1999. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Mol. Endocrinol. 13:1801-1810.
101. Thapar, K., Scheithauer, B.W., Kovacs, K., Pernicone, P.J., and Laws, E.R., Jr. 1996. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:763-770; discussion 770-771.
102. Levy, A., Hall, L., Yeudall, W.A., and Lightman, S.L. 1994. p53 gene mutations in pituitary adenomas: rare events. Clin. Endocrinol. (Oxf). 41:809-814.
103. Zhang, X., et al. 2002. Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 87:1262-1267.
104. Cruz-Soto, M.E., Scheiber, M.D., Gregerson, K.A., Boivin, G.P., and Horseman, N.D. 2002. Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology. 143:4429-4436.
105. Pei, L., Melmed, S., Scheithauer, B., Kovacs, K., and Prager, D. 1994 H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metab. 78:842-846.
106. Heaney, A.P., Fernando, M., and Melmed, S. 2003. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111:1381-1388. doi:10.1172/JCI200316575.
107. Wynick, D., et al. 1998. Galanin regulates prolactin release and lactotroph proliferation. Proc. Natl. Acad. Sci. U. S. A. 95:12671-12676.
108. Hui, A.B., Pang, J.C., Ko, C.W., and Ng, H.K. 1999. Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization. Hum. Pathol. 30:1019-1023.
109. Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1998. Genetic instabilities in human cancers. Nature. 396:643-649.
110. Zimonjic, D., Brooks, M.W., Popescu, N., Weinberg, R.A., and Hahn, W.C. 2001. Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res. 61:8838-8844.
111. Pei, L., and Melmed, S. 1997. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11:433-441.
112. Heaney, A.P., et al. 2000. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet. 355:716-719.
113. Saez, C., et al. 1999. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene. 18:5473-5476.
114. Zhang, X., et al. 1999. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 84:761-767.
115. Zhang, X., et al. 1999. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 13:156-166.
116. Pei, L. 2000. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J. Biol. Chem. 275:31191-31198.
117. McCabe, C.J., et al. 2003. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin. Endocrinol. (Oxf). 58:141-150.
118. McCabe, C.J., et al. 2002. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 87:4238-4244.
119. Turner, H.E., et al. 2000. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J. Endocrinol. 165:475-481.
120. Horwitz, G.A., Miklovsky, I., Heaney, A.P., Ren, S.G., and Melmed, S. 2003. Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol. Endocrinol. 17:600-609.
121. Zou, H., McGarry, T.J., Bernal, T., and Kirschner, M.W. 1999. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418-422.
122. Nasmyth, K. 2002. Segregating sister genomes: the molecular biology of chromosome separation. Science. 297:559-565.
123. Jallepalli, P.V., et al. 2001. Securin is required for chromosomal stability in human cells. Cell 105:445-457.
124. Stemmann, O., Zou, H., Gerber, S.A., Gygi, S.P., and Kirschner, M.W. 2001. Dual inhibition of sister chromatid separation at metaphase. Cell. 107:715-726.
125. Wang, Z., Yu, R., and Melmed, S. 2001. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocrinol. 15:1870-1879.
126. Hauf, S., Waizenegger, I.C., and Peters, J.M. 2001. Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. Science. 293:1320-1323.
127. Ramos-Morales, F., et al. 2000. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene. 19:403-409.
128. Yu, R., Ren, S.G., Horwitz, G.A., Wang, Z., and Melmed, S. 2000. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol. Endocrinol. 14:1137-1146.
129. Yu, R., Lu, W., and Melmed, S. 2003. Overexpressed pituitary tumor transforming gene (PTTG) causes aneuploidy in live human cells. Endocrinology. 144:4991-4998.
130. Yu, R., Heaney, A.P., Lu, W., Chen, J., and Melmed, S. 2000. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J. Biol. Chem. 275:36502-36505.
131. Bernal, J.A., et al. 2002. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet. 32:306-311.
132. Zur, A., and Brandeis, M. 2001. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. Embo J. 20:792-801.
133. Abbud, R., et al. 2003. Molecular pathogenesis. In 8th International Pituitary Congress. Pituitary Society, New York, New York, USA. (Abstr. S1)
134. Wang, Z., Moro, E., Kovacs, K., Yu, R., and Melmed, S. 2003. Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc. Natl. Acad. Sci. U. S. A. 100:3428-3432.
135. Ramaswamy, S., Ross, K.N., Lander, E.S., and Golub, T.R. 2003. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:49-54.
136. Verges, B., et al. 2002. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87:457-465.
137. Shimon, I., et al. 1997. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. 100:2386-2392.
138. Riley, D.J., Nikitin, A.Y., and Lee, W.H. 1996. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nat. Med. 2:1316-1321.
139. Melmed, S., and Kleinberg, D.L. 2003. Anterior pituitary. In Williams textbook of endocrinology. P. Larsen, H.M. Kronenberg, S. Melmed, and K.S. Polonsky, editors. W.B. Saunders. Philadelphia, Pennsylvania, USA. 177-279.
140. Shimon, I., and Melmed, S. 1997. Anterior pituitary hormones. In Endocrinology: basic and clinical principles. P.M. Conn, and S. Melmed, editors. Humana Press. Totowa, New Jersey, USA. 211-222.
141. Amselem, S. 2001. Perspectives on the molecular basis of developmental defects in the human pituitary region. In Hypothalamic-pituitary development: genetic and clinical aspects. R. Rappaport, and S. Amselem, editors. S. Karger Publishing. Basel, Switzerland. 30-47.
142. Schmitt, C.A. 2003. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat. Rev. Cancer. 3:286-295.
143. Yu, R. and Melmed, S. 2001. Oncogene activation in pituitary tumors. Brain Pathology. 11:328-341.
144. Clayton, R.N. 1999. Sporadic pituitary tumors: from epidemiology to use of databases. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 13:451-460.
145. Kovacs, K., and Horvath, E. 1986. Pathology of growth hormone-producing tumors of the human pituitary. Semin. Diagn. Pathol. 3:18-33.
146. Scheithauer, B.W., Horvath, E., Lloyd, R.V., and Kovacs, K. 1994. Pathology of pituitary adenomas and pituitary hyperplasia. In Diagnosis and management of pituitary tumors. K. Thapar, K. Kovacs, B. Scheitnauer, and R. Lloyd, editors. Humana Press Inc. Totowa, New Jersey, USA. 91-154.
147. Minderman, T., and Wilson, C.B. 1994. Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxf). 41:359-364.
148. Asa, S.L., Horvath, E., and Kovacs, K. 1993. Pituitary neoplasms: an overview of the clinical presentation, diagnosis, treatment and pathology. In Endocrine tumours. E.L. Mazzaferri and N.A. Samaan, editors. Blackwell Scientific Publications. Boston, Massachusetts, USA. 77-112.
149. Prezant, T., and Melmed, S. 1998. Pituitary oncogenes. In Pituitary tumours: epidemiology, pathogenesis and management. S.M. Webb, editor. Bioscientifica. Bristol, United Kingdom. 81-93.